Skip to search formSkip to main contentSkip to account menu

refractory chronic lymphocytic leukemia

Known as: Refractory CLL, chronic lymphocytic leukemia, refractory, Refractory Chronic Lymphoid Leukemia 
Chronic lymphocytic leukemia that is resistant to treatment.
National Institutes of Health

Related topics

Related topics

26 relations
Atypical lymphocyteB lymphoblastB-LymphocytesBCL3 gene

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Impact of Number of Prior Therapies and Bulk of Disease on Outcomes with Venetoclax (VEN) Monotherapy for Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Background: The BCL-2 inhibitorVEN is an effective therapy for patients (pts) with relapsed/refractory (R/R) CLL, including those… 
2016
2016
Pooled Multi-Trial Analysis of Venetoclax Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
Background: The oral selective BCL-2 inhibitor, venetoclax, is FDA-approved for the treatment of Chronic Lymphocytic Leukemia… 
2016
2016
Detailed Safety Analysis of Venetoclax Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Background: Venetoclax (VEN) is a selective, potent, orally bioavailable BCL-2 inhibitor FDA-approved for patients with del(17p… 
2013
2013
Ofatumumab in combination with high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia.
7124 Background: We performed a phase II, single-arm, clinical trial evaluating ofatumumab in combination with HDMP for the… 
2013
2013
Lenalidomide and Rituximab For The Treatment Of Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results Of Planned Interim Analysis
Based on data previously presented by our group demonstrating the safety and efficacy of lenalidomide (L) and rituximab (R) in… 
Review
2008
Review
2008
Effect of the addition of oblimersen (Bcl-2 antisense) to fludarabine/cyclophosphamide for relapsed/refractory chronic lymphocytic leukemia (CLL) on survival in patients who achieve CR/nPR: Five-year…
7008 Background: Bcl-2 upregulation is critical in the pathogenesis and progression of CLL. OBL enhances the cytotoxic activity… 
2008
2008
A phase I trial for the treatment of purine analog-refractory chronic lymphocytic leukemia using autologous T cells genetically targeted to the B cell specific antigen CD19
3045 Background: We have developed a novel immunotherapy strategy based on the genetic modification of patient T cells to… 
2005
2005
Low frequency of exon 3 PTPN11 mutations in adult de novo acute myeloid leukemia. Analysis of a consecutive series of 173 patients.
A total of 173 samples obtained from adult patients with de novo acute myeloid leukemia (AML) were assayed for exon 3 PTPN11… 
2005
2005
Low-dose intravenous alemtuzumab therapy in pretreated patients affected by chronic lymphocytic leukemia. A single center experience.
We report the efficacy and safety of intravenous low-dose alemtuzumab (10 mg three times weekly for 10 weeks) in 12 patients with… 
2004
2004
Rituximab® and High Dose Methylprednisolone (HDMP) for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.
High-dose gluocorticoids and the anti-CD20 mAb Rituximab each can effect partial responses in patients with chronic lymphocytic…